Differential antibody responses to gliadin-derived indigestible peptides in patients with schizophrenia

RT McLean, P Wilson, D St Clair, CJ Mustard, J Wei

Research output: Contribution to journalArticle

5 Citations (Scopus)
5 Downloads (Pure)

Abstract

Gluten consumption has previously been implicated in the development of schizophrenia, while an immunological link between gluten and schizophrenia was established by the detection of circulating antibodies against gliadin, a major component of wheat gluten. Several studies have reported an increase in circulating antibodies against native gliadin molecules that are unlikely to survive degradation in the digestive system. In this study, therefore, we measured plasma IgG and IgA antibodies against indigestible gliadin-derived peptide antigens using an in-house enzyme-linked immunosorbent assay (ELISA) among 169 patients with schizophrenia and 236 control subjects. We also examined plasma levels of IgG and IgA antibodies against the mixture of native gliadins using commercially available ELISA kits. The results showed that patients with schizophrenia had increased levels of plasma IgG against the γ-gliadin derived fragment, namely AAQ6C, but decreased levels of plasma IgG against α- and γ3-gliadin derived antigens, as compared with control subjects. This study also demonstrated a uniform decrease in plasma IgA antibodies against gliadin-derived antigens. There was no significant difference in the levels of plasma antibodies against native gliadins between the patient group and the control group. Of 8 gliadin-derived antigens tested, 4 showed a sensitivity of >20% against the specificity of ≥95% for detection of their corresponding antibodies in plasma. These 4 tests may thus have a potential to serve as biomarkers for identification of schizophrenia subgroups that may need an alternative therapy or precision treatment. Further investigation with clinical trials should be carried out to explore this possibility.
Original languageEnglish
Article numbere1121
JournalTranslational Psychiatry
Volume7
Early online date9 May 2017
DOIs
Publication statusPublished - 2017

Fingerprint

Gliadin
Antibody Formation
Schizophrenia
Peptides
Antibodies
Glutens
Immunoglobulin G
Immunoglobulin A
Antigens
Enzyme-Linked Immunosorbent Assay
Digestive System
Complementary Therapies
Triticum
Biomarkers
Clinical Trials
Control Groups

Keywords

  • schizophrenia
  • wheat gluten
  • anti-gluten antibodies
  • ELISA
  • psychoneuroimmunology

Cite this

Differential antibody responses to gliadin-derived indigestible peptides in patients with schizophrenia. / McLean, RT ; Wilson, P; St Clair, D; Mustard, CJ ; Wei, J.

In: Translational Psychiatry, Vol. 7, e1121, 2017.

Research output: Contribution to journalArticle

@article{bf605b9ed6e94ffaac743a03d3080c9a,
title = "Differential antibody responses to gliadin-derived indigestible peptides in patients with schizophrenia",
abstract = "Gluten consumption has previously been implicated in the development of schizophrenia, while an immunological link between gluten and schizophrenia was established by the detection of circulating antibodies against gliadin, a major component of wheat gluten. Several studies have reported an increase in circulating antibodies against native gliadin molecules that are unlikely to survive degradation in the digestive system. In this study, therefore, we measured plasma IgG and IgA antibodies against indigestible gliadin-derived peptide antigens using an in-house enzyme-linked immunosorbent assay (ELISA) among 169 patients with schizophrenia and 236 control subjects. We also examined plasma levels of IgG and IgA antibodies against the mixture of native gliadins using commercially available ELISA kits. The results showed that patients with schizophrenia had increased levels of plasma IgG against the γ-gliadin derived fragment, namely AAQ6C, but decreased levels of plasma IgG against α- and γ3-gliadin derived antigens, as compared with control subjects. This study also demonstrated a uniform decrease in plasma IgA antibodies against gliadin-derived antigens. There was no significant difference in the levels of plasma antibodies against native gliadins between the patient group and the control group. Of 8 gliadin-derived antigens tested, 4 showed a sensitivity of >20{\%} against the specificity of ≥95{\%} for detection of their corresponding antibodies in plasma. These 4 tests may thus have a potential to serve as biomarkers for identification of schizophrenia subgroups that may need an alternative therapy or precision treatment. Further investigation with clinical trials should be carried out to explore this possibility.",
keywords = "schizophrenia, wheat gluten , anti-gluten antibodies, ELISA, psychoneuroimmunology",
author = "RT McLean and P Wilson and {St Clair}, D and CJ Mustard and J Wei",
note = "We thank the patients and healthy volunteers for their support and participation. We also thank NHS Grampian for sample collection and our colleagues at the Division of Health Research, University of the Highlands and Islands, for their supportive work. This study was supported by the Schizophrenia Association of Great Britain, Bangor, UK.",
year = "2017",
doi = "10.1038/tp.2017.89",
language = "English",
volume = "7",
journal = "Translational Psychiatry",
issn = "2158-3188",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Differential antibody responses to gliadin-derived indigestible peptides in patients with schizophrenia

AU - McLean, RT

AU - Wilson, P

AU - St Clair, D

AU - Mustard, CJ

AU - Wei, J

N1 - We thank the patients and healthy volunteers for their support and participation. We also thank NHS Grampian for sample collection and our colleagues at the Division of Health Research, University of the Highlands and Islands, for their supportive work. This study was supported by the Schizophrenia Association of Great Britain, Bangor, UK.

PY - 2017

Y1 - 2017

N2 - Gluten consumption has previously been implicated in the development of schizophrenia, while an immunological link between gluten and schizophrenia was established by the detection of circulating antibodies against gliadin, a major component of wheat gluten. Several studies have reported an increase in circulating antibodies against native gliadin molecules that are unlikely to survive degradation in the digestive system. In this study, therefore, we measured plasma IgG and IgA antibodies against indigestible gliadin-derived peptide antigens using an in-house enzyme-linked immunosorbent assay (ELISA) among 169 patients with schizophrenia and 236 control subjects. We also examined plasma levels of IgG and IgA antibodies against the mixture of native gliadins using commercially available ELISA kits. The results showed that patients with schizophrenia had increased levels of plasma IgG against the γ-gliadin derived fragment, namely AAQ6C, but decreased levels of plasma IgG against α- and γ3-gliadin derived antigens, as compared with control subjects. This study also demonstrated a uniform decrease in plasma IgA antibodies against gliadin-derived antigens. There was no significant difference in the levels of plasma antibodies against native gliadins between the patient group and the control group. Of 8 gliadin-derived antigens tested, 4 showed a sensitivity of >20% against the specificity of ≥95% for detection of their corresponding antibodies in plasma. These 4 tests may thus have a potential to serve as biomarkers for identification of schizophrenia subgroups that may need an alternative therapy or precision treatment. Further investigation with clinical trials should be carried out to explore this possibility.

AB - Gluten consumption has previously been implicated in the development of schizophrenia, while an immunological link between gluten and schizophrenia was established by the detection of circulating antibodies against gliadin, a major component of wheat gluten. Several studies have reported an increase in circulating antibodies against native gliadin molecules that are unlikely to survive degradation in the digestive system. In this study, therefore, we measured plasma IgG and IgA antibodies against indigestible gliadin-derived peptide antigens using an in-house enzyme-linked immunosorbent assay (ELISA) among 169 patients with schizophrenia and 236 control subjects. We also examined plasma levels of IgG and IgA antibodies against the mixture of native gliadins using commercially available ELISA kits. The results showed that patients with schizophrenia had increased levels of plasma IgG against the γ-gliadin derived fragment, namely AAQ6C, but decreased levels of plasma IgG against α- and γ3-gliadin derived antigens, as compared with control subjects. This study also demonstrated a uniform decrease in plasma IgA antibodies against gliadin-derived antigens. There was no significant difference in the levels of plasma antibodies against native gliadins between the patient group and the control group. Of 8 gliadin-derived antigens tested, 4 showed a sensitivity of >20% against the specificity of ≥95% for detection of their corresponding antibodies in plasma. These 4 tests may thus have a potential to serve as biomarkers for identification of schizophrenia subgroups that may need an alternative therapy or precision treatment. Further investigation with clinical trials should be carried out to explore this possibility.

KW - schizophrenia

KW - wheat gluten

KW - anti-gluten antibodies

KW - ELISA

KW - psychoneuroimmunology

U2 - 10.1038/tp.2017.89

DO - 10.1038/tp.2017.89

M3 - Article

VL - 7

JO - Translational Psychiatry

JF - Translational Psychiatry

SN - 2158-3188

M1 - e1121

ER -